Articles On Zelda Therapeutics (ASX:ZLD)

Title Source Codes Date
Zelira Therapeutics, Emyria join hands to trial HOPE™ Products for Autism patients

Summary Leading biopharmaceutical company Zelira Therapeutics signed an agreement with Emyria Ltd for Autism Observational Trial of HOPE™ products. The Trial will collect efficacy and safety data from patients diagnosed with ASD and ha...

Kalkine Media ZLD 3 years ago
Drawbacks of the TGA’s cannabis changes for listed pot stocks

Having been subject to a harsh reality check over the last year or so, the ASX-listed cannabis sector is applauding the local medicine regulator’s endorsement of the weed as an effective therapy that should be more freely available to the a...

SmallCaps ZLD 3 years ago
ScoPo’s health powerplays: Pot stocks get a boost

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes for the week It’s been...

Stockhead ZLD 3 years ago
Zelira to launch new hemp-derived toothpaste in the US

Listed cannabis company Zelira Therapeutics (ASX: ZLD) has today formed a new Oral Care products subsidiary, tasked with selling a hemp-derived cannabinoid-based toothpaste. The company plans on launching the toothpaste product in the USA...

BusinessNewsAus ZLD 3 years ago
Zelira to launch new hemp-derived toothpaste in the US

Listed cannabis company Zelira Therapeutics (ASX: ZLD) has today formed a new Oral Care products subsidiary, tasked with selling a hemp-derived cannabinoid-based toothpaste. The company plans on launching the toothpaste product in the USA...

BusinessNewsAus ZLD 3 years ago
Zelira Therapeutics (ASX:ZLD) launches oral care subsidiary in US

08 Sep 2020 - Global therapeutic medicinal cannabis company, Zelira Therapeutics (ASX:ZLD) has expanded into the dental health market by launching a scientifically formulated, hemp…

FNN ZLD 3 years ago
Scopo’s powerplays: Investors love an ice queen

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With repor...

Stockhead ZLD 3 years ago
Health Kick: Zelira’s cannabis-derived insomnia treatment has investors dreaming

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the pen and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Dr Richard Hopkins, Managing Director of Zeli...

Stockhead ZLD 3 years ago
Scopo’s powerplays: Strap yourselves in for some M&A

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The pundit...

Stockhead ZLD 3 years ago
Zelira partners with US research centre to treat symptoms of diabetes complications

Zelira (ASX: ZLD) has partnered with US-based Cardiovascular Solutions of Central Mississippi (CVSCM) to develop and commercialise CBD and hemp products to target symptoms associated with Peripheral Arterial Disease (PAD) and Diabetic Neuro...

BusinessNewsAus ZLD 3 years ago
Zelira Therapeutics targets arterial disease and diabetic illnesses with medicinal cannabis

Medical cannabis company Zelira Therapeutics (ASX: ZLD) has committed to a binding five-year agreement with US-based company Cardiovascular Solutions of Central Mississippi (CVSCM) to develop and commercialise products to treat symptoms ass...

SmallCaps ZLD 3 years ago
Scopo’s health powerplays: quick vaccine hits and cheap buys

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The market...

Stockhead ZLD 3 years ago
Pot stock Zelira Therapeutics successfully passes another Phase I clinical trial

Zelira Therapeutics (ASX:ZLD) has completed another medicinal cannabis trial and passed with flying colours. This time it was a Phase 1 dose escalation study assessing the safety of its cannabis formulation in chronic pain patients using op...

Stockhead ZLD 3 years ago
Scopo’s health powerplays: You’re all going to the pot, literally

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week As markets...

Stockhead ZLD 3 years ago
COVID-19 hasn’t hurt cannabis clinical trials … much

Since the start of March, six clinical trials involving cannabis treatments around the world have been halted or cancelled altogether due to COVID19 pandemic but 179 are still recruiting, according to the US registry ClinicalTrials.com. Mor...

Stockhead ZLD 3 years ago
Zelira Therapeutics inks manufacturing deal with TasAlk

Australian medicinal cannabis company Zelira Therapeutics (ASX:ZLD) has announced a commercial supply agreement with Tasmanian Alkaloids (TasAlk) to manufacture the Insomnia and HOPE medicinal cannabis formulations.

BiotechDispatch ZLD 3 years ago
Zelira Therapeutics says ZLT-101 on track to launch later this year

Perth-based medicinal cannabis company Zelira Therapeutics (ASX:ZLD) has announced it has demonstrated its formulation ZLT-101 works for people suffering insomnia. 

BiotechDispatch ZLD 3 years ago
Zelira Therapeutics reveals more positive results from medical cannabis trial to treat insomnia

Zelira Therapeutics (ASX: ZLD) has announced its Phase 1b/2a medicinal cannabis trial to treat insomnia has met both its primary and secondary endpoints. The company today confirmed it has received the final clinical report for the trial, w...

SmallCaps ZLD 3 years ago
Zelira, PolyNovo prove even a pandemic can’t stand in the way of good clinical results

In proof that biotechs will deliver market returns even during a pandemic, two companies this morning have issued clinical trial results and watched their share prices rocket. Pot stock Zelira Therapeutics (ASX:ZLD) has received the full re...

Stockhead ZLD 3 years ago
Dr Boreham’s Crucible: Zelira’s share price could wake up once sales of its pot-based insomnia drug start

Zelira Therapeutics (ASX:ZLD) chief Dr Richard Hopkins confirms what your columnist suspected was a self-serving myth perpetuated by overzealous users of the intoxicating herb: no one has ever been recorded as overdosing on cannabis over mi...

Stockhead ZLD 3 years ago
Zelira updates on trial in patients on opioid treatment

Medicinal cannabis company Zelira Therapeutics (ASX:ZLD) says its Phase 1 Dose Escalation Trial in patients on long-term opioid treatment is now fully enrolled.

BiotechDispatch ZLD 4 years ago
Cannabis: Another German importer wants Little Green Pharma’s products

Little Green Pharma (ASX:LGP) announced a new export partner — and it happens to be the only company covering the entire medicinal cannabis production chain. Berlin-based Deutsche Medizinalcannabis (Demecan) will import and sell LGP’s Class...

Stockhead ZLD 4 years ago
Zelira is worshipping at the FDA altar hoping it will smite enemies

Two years ago Zelira (ASX:ZLD) — then Zelda — was set to invade the German market, planning to storm the walls with unregistered marijuana products that had a little bit of clinical data behind them, data which would be the reason for a big...

Stockhead ZLD 4 years ago
Health: Compumedics wins FDA approval for its brain scanners, leaps 20pc

Another ASX small cap has won the blessing of the Food and Drug Administration (FDA) for its products enter the US market. This morning it was Compumedics (ASX:CMP). Its signature product, the Orion LifeSpan Magnetoencephalography single De...

Stockhead ZLD 4 years ago
Zelira Therapeutics completes capital raise

Medicinal cannabis company Zelira Therapeutics (ASX:ZLD) has completed a placement of 91,770,000 fully-paid ordinary shares at a share price of $0.05 to Australian and International investors.

BiotechDispatch ZLD 4 years ago
Zelira Therapeutics (ASX: ZLD) raises $4.5M to launch new products in 2020

Therapeutic medicinal cannabis company, Zelira Therapeutics (ZLD) has successfully completed a $4.5 million placement The placement was fully supported by existing and new shareholders Funds will be used to launch new products into the glo...

themarketherald.com.au ZLD 4 years ago
Cannabis: Elixinol Global kills medical pot, holds fire sale for Aussie hemp

Elixinol Global (ASX:EXL) is bleeding money and is holding a fire sale of its global hemp and medical cannabis assets. Today the company said it was selling its Hemp Foods Australia subsidiary to a Chinese buyer for just $500,000. It is kil...

Stockhead ZLD 4 years ago
My bank balance is bigger than yours: biotech quarterlies

Quarterly reports for biotechs usually only tell investors how much cash they have left — and how much time they have until the next cap raise. But December quarterlies from late Friday and today include several companies that are making mo...

Stockhead ZLD 4 years ago
Zelira Therapeutics partners with US-based Parkinson’s Foundation

Zelira Therapeutics (ASX:ZLD) has announced a collaboration with the US-based Parkinson’s Foundation to gather insights from people with PD about their understanding of and use of medical cannabis and hemp-derived therapies.

BiotechDispatch ZLD 4 years ago
NT pot scripts stand at 1 as industry begs govt to act on patient access

Only one prescription for medical marijuana has been issued by a doctor in the Northern Territory, according to Minister for Health Natasha Fyles. In a submission to the Senate inquiry into barriers to patient access to marijuana, Fyles sai...

Stockhead ZLD 4 years ago
The US legal pot market is massive and confusing: report

For an industry that’s projected to reach $US20 billion ($29 billion) by 2024 in the US, the cannabidiol (CBD) market there is very much the wild west. A study from researcher Leafreport comparing 3500 products for the sale in the US from 5...

Stockhead ZLD 4 years ago
Who changed their name in 2019?

There are many reasons why a company might change its name, from being taken over to hiding a shady past. This year 114 companies have changed their name. Family cyber security provider Wangle Technologies became the much more fitting Famil...

Stockhead ZLD 4 years ago
Cannabis stocks guide: Here’s everything you need to know

Marijuana is the hottest herb on the planet right now, but while investing in medical cannabis stocks could make you a fortune, it could also risk the house. After a flurry of activity on the ASX in 2017 as the sector kicked off following l...

Stockhead ZLD 4 years ago
Casting Eye on recent IPOs, Healthcare player Emerald Clinics follows suit

An Initial Public Offering (IPO) is a process in which a private company offers its shares to the public through stock issuance. An IPO is the best way for a company to raise a substantial amount of capital to expand its operations. The fun...

Kalkine Media ZLD 4 years ago
Zelira Therapeutics Completes Last Patient Dosing in Clinical Trial

Zelira Therapeutics Limited (ASX: ZLD) has announced that last patient has completed dosing in its pioneering medicinal cannabis trial cannabis for insomnia. The company expects to report half-year results by February 2020. It is said that...

Kalkine Media ZLD 4 years ago
Health: NZ restricts codeine, painkiller stocks celebrate

New Zealand’s medicines regulator has recommended the country fall in line with Australia’s new codeine restrictions, and pharmaceutical companies are backing the decision. Yesterday, Medsafe recommended that all medications containing code...

Stockhead ZLD 4 years ago
Zelda Therapeutics (ASX:ZLD) name change

05 Dec 2019 - Zelda Therapeutics (ASX:ZLD) has confirmed the company has changed its name to Zelira Therapeutics.

FNN ZLD 4 years ago
Cannabis: THC Global hits milestone with first cannabis production at Southport

Pot stock THC Global (ASX:THC) is in business at Southport, the largest medicinal cannabis production hub in the southern hemisphere. The company announced the release of its completed Canndeo line of cannabis medicines, cultivated using ma...

Stockhead ZLD 4 years ago
THC Global share price surges 11% higher on cannabis production update

The THC Global Group Ltd (ASX: THC) share price has returned from its trading halt and surged higher. At the time of writing the cannabis company’s shares are up 11% to 41 cents. Why were THC Global’s shares in a trading halt? THC Global r...

Motley Fool ZLD 4 years ago
Zelira confirms completion of acquisition

Zelira Therapeutics, formerly known as Zelda Therapeutics (ASX:ZLD), has announced the completion of the 100 per cent acquisition of Ilera Therapeutics.

BiotechDispatch ZLD 4 years ago
Health House Holdings to distribute Zelda Therapeutics’ medicinal cannabis throughout Australasia and UK

Zelda Therapeutics’ (ASX: ZLD) medicinal cannabis products will be distributed across Australasia and the United Kingdom under a new agreement with Health House Holdings Ltd. The agreement follows Zelda’s intent to launch its HOPE products...

SmallCaps ZLD 4 years ago
Zelda Therapeutics does distribution deal for Australasia and UK

This is a strategic and non-exclusive agreement which opens the door into some of the world’s fastest growing cannabis markets.

Proactive Investors ZLD 4 years ago
Weed Week: In Thailand you’ll be able to grow cannabis ‘like any other herb’

Thailand has not yet legalised marijuana but pretty soon Thais will not only be able to grow their own plants but they will be allowed to sell them to the government. “In the near future, families will be able to plant cannabis trees in the...

Stockhead ZLD 4 years ago
Zelda Therapeutics aims to launch medicinal cannabis HOPE® range early 2020

Zelda recently detailed its intention to merge with Ilera Therapeutics to create a leading medicinal cannabis company rebranded Zelira Therapeutics.

Proactive Investors ZLD 4 years ago
Zelda Therapeutics to supply its cannabis medicine to cancer patients in Newcastle trial

Zelda will be one of several suppliers in the clinical trial seeking to enrol up to 600 advanced cancer patients.

Proactive Investors ZLD 4 years ago
Zelda cannabis formulations to be supplied to the CARE NSW trial

Zelda Therapeutics (ASX:ZLD) has entered a new agreement with the NHMRC-funded Australian Centre for Clinical Cannabinoid Research Excellence, based at the University of Newcastle, to commercially supply a cannabis oil formulation....

BiotechDispatch ZLD 4 years ago
Zelda Therapeutics banks $982,000 R&D cash ahead of Ilera Therapeutics merger vote

The tax refund will be used on the cannabinoid-based therapeutics developer’s program as it plans product roll-outs next year.

Proactive Investors ZLD 4 years ago
Zelda Therapeutics completes enrolment for insomnia trial

The pioneering medicinal cannabis clinical trial for insomnia is treating 24 patients at the University of Western Australia sleep centre.

Proactive Investors ZLD 4 years ago
Zelda Therapeutics announces insomnia clinical trial is fully enrolled

Medicinal cannabis company Zelda Therapeutics (ASX:ZLD) has announced that its clinical trial for insomnia is now fully enrolled. 

BiotechDispatch ZLD 4 years ago
SUDA Pharmaceuticals inks deal with Cann Pharmaceutical to develop medical cannabis oral spray

Drug delivery specialist SUDA Pharmaceuticals (ASX: SUD) has finalised a deal with medical cannabis company Cann Pharmaceutical Australia that will see the pair develop an oro-mucosal spray to treat drug-resistant epilepsy, melanoma and mot...

SmallCaps ZLD 4 years ago